GURUFOCUS.COM » STOCK LIST » Technology » Software » Vivo Collaboration Solutions Ltd (NSE:VIVO) » Definitions » Total Current Liabilities

Vivo Collaboration Solutions (NSE:VIVO) Total Current Liabilities : ₹9.72 Mil (As of Mar. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Vivo Collaboration Solutions Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Vivo Collaboration Solutions's total current liabilities for the quarter that ended in Mar. 2023 was ₹9.72

Vivo Collaboration Solutions Total Current Liabilities Historical Data

The historical data trend for Vivo Collaboration Solutions's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivo Collaboration Solutions Total Current Liabilities Chart

Vivo Collaboration Solutions Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23
Total Current Liabilities
26.81 37.77 31.30 6.83 9.72

Vivo Collaboration Solutions Semi-Annual Data
Mar19 Mar20 Mar21 Mar22 Mar23
Total Current Liabilities 26.81 37.77 31.30 6.83 9.72

Vivo Collaboration Solutions Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Vivo Collaboration Solutions's Total Current Liabilities for the fiscal year that ended in Mar. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=7.081+0
+Other Current Liabilities+Current Deferred Liabilities
=2.639+0
=9.72

Vivo Collaboration Solutions's Total Current Liabilities for the quarter that ended in Mar. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=7.081+0
+Other Current Liabilities+Current Deferred Liabilities
=2.639+0
=9.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Vivo Collaboration Solutions Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Vivo Collaboration Solutions's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivo Collaboration Solutions (NSE:VIVO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Technology » Software » Vivo Collaboration Solutions Ltd (NSE:VIVO) » Definitions » Total Current Liabilities
Comparable Companies
BOM:532402 BOM:512405 BOM:543938 NSE:GSTL NSE:TRIDHYA MSFT ORCL ADBE PANW SNPS VMW FTNT CRWD PLTR SQ SPLK MDB ZS XAMS:ADYEN VRSN
Traded in Other Exchanges
N/A
Address
315, Third Floor, HB Twin Tower, Netaji Subhash Place, Pitampura, North Delhi, Delhi, IND, 110034
Website
https://www.vivo.ooo
Vivo Collaboration Solutions Ltd is a Cloud Telephony service provider. The company offers comprehensive suite of telephony services, covering every voice-based solution. It delivers end-to-end Cloud Telephony solutions for enterprises. The company provides conceivable collaboration and online meeting solution, unified conferencing, web conferencing, audio conferencing, webinars, webcasts, events, Instant Messaging Services and more.

Vivo Collaboration Solutions (NSE:VIVO) Headlines

From GuruFocus

Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference

By PRNewswire PRNewswire • 07-02-2022

Meridian Bioscience responds to the Monkeypox Outbreak with its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests

By PRNewswire PRNewswire • 06-15-2022

Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference

By PRNewswire PRNewswire • 07-12-2022

Chuck Royce Buys 1, Sells 4 in 3rd Quarter

By GuruFocus Research GuruFocus Editor • 11-03-2022

MERIDIAN BIOSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Meridian Bioscience, Inc. - VIVO

By Business Wire Business Wire • 07-08-2022

SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience

By PRNewswire PRNewswire • 01-31-2023

Meridian Bioscience Launches Lyo-Ready� Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays

By PRNewswire PRNewswire • 06-16-2022

Shareholder Alert: Ademi LLP investigates whether Meridian Bioscience, Inc. has obtained a Fair Price in its transaction with the Consortium

By PRNewswire PRNewswire • 07-07-2022

MERIDIAN BIOSCIENCE ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of VIVO and Encourages Investors to Contact the Firm

By PurpleRose PurpleRose • 07-11-2022

MERIDIAN BIOSCIENCE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Meridian Bioscience, Inc. - VIVO

By PRNewswire PRNewswire • 07-28-2022